STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

Guardant Health (GH) CTO exercises 10,714 PSUs; 5,759 shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health Chief Technology Officer Darya Chudova exercised performance-based equity and had shares withheld for taxes. On March 15, 2026, a performance-based restricted stock unit award covering 10,714 units converted into 10,714 shares of common stock after the second performance tranche was achieved.

The company then withheld 5,759 of those common shares, valued at $85.49 per share, to cover tax obligations associated with the vesting, as disclosed in the footnotes. After these transactions, Chudova directly held 64,352 shares of Guardant Health common stock, reflecting a routine compensation-related equity increase rather than an open-market trade.

Positive

  • None.

Negative

  • None.
Insider Chudova Darya
Role Chief Technology Officer
Type Security Shares Price Value
Exercise Performance-Based Restricted Stock Units 10,714 $0.00 --
Exercise Common Stock 10,714 $0.00 --
Tax Withholding Common Stock 5,759 $85.49 $492K
Holdings After Transaction: Performance-Based Restricted Stock Units — 0 shares (Direct); Common Stock — 70,111 shares (Direct)
Footnotes (1)
  1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026. Not applicable for Restricted Stock Units.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chudova Darya
(Last) (First) (Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/15/2026 M 10,714 A $0 70,111 D
Common Stock 03/15/2026 F 5,759(1) D $85.49 64,352 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance-Based Restricted Stock Units $0 03/15/2026 M 10,714 (2) (3) Common Stock 10,714 $0 0 D
Explanation of Responses:
1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
2. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Darya Chudova 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Guardant Health (GH) report for Darya Chudova?

Guardant Health reported that Chief Technology Officer Darya Chudova exercised 10,714 performance-based restricted stock units into common shares. This was a scheduled vesting tied to a performance metric and not an open-market purchase or sale of stock.

How many Guardant Health shares were withheld for taxes in this Form 4?

The company retained 5,759 common shares at $85.49 per share to satisfy tax withholding obligations. The footnotes state the amount withheld did not exceed the related tax liability arising from the vesting of the restricted stock units.

What award did Darya Chudova exercise according to Guardant Health’s Form 4?

The Form 4 shows exercise of a performance-based restricted stock unit award originally granted on June 7, 2023. It carried a three-year performance metric; the second tranche target was achieved, and 10,714 units vested on March 15, 2026.

How many Guardant Health shares does Darya Chudova own after this Form 4 transaction?

Following the exercise and tax withholding, Darya Chudova directly holds 64,352 shares of Guardant Health common stock. This figure reflects her post-transaction ownership and indicates she retained a substantial equity position after the compensation-related vesting.

Was the Guardant Health Form 4 transaction an open-market sale or purchase?

No, the Form 4 does not report an open-market trade. It records derivative exercise of performance-based restricted stock units and a tax-withholding disposition, where shares were retained by the company to cover tax obligations from the vesting event.